Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins

Podobne zapisy

• Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations
  od: Wasan, Kishor M., i wsp.
  Wydane: (2003)
• Lipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels
  od: Wasan, Kishor M., i wsp.
  Wydane: (1999)
• Suppression of Murine Endotoxin Response by E5531, a Novel Synthetic Lipid A Antagonist
  od: Kobayashi, Seiichi, i wsp.
  Wydane: (1998)
• Amphotericin B Lipid Complex or Amphotericin B Multiple-Dose Administration to Rabbits with Elevated Plasma Cholesterol Levels: Pharmacokinetics in Plasma and Blood, Plasma Lipoprotein Levels, Distribution in Tissues, and Renal Toxicities
  od: Ramaswamy, Manisha, i wsp.
  Wydane: (2001)
• Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers
  od: Rossignol, Daniel P., i wsp.
  Wydane: (2004)